The rise of serotype O26:H11 as a Shiga toxin producing E. coli serotype of concern in New Zealand. A presentation delivered at the VTEC 2026 (held from 10 - 13 May 2026) in Aberdeen Scotland
Year: 2026
Type: article
Abstract: Historically in Aotearoa New Zealand (NZ), the primary serotype of concern for Shiga toxin producing E. coli (STEC) infections has been O157:H7 based on its higher likelihood of hospitalisation and progression to severe disease. This serotype is also readily recognisable on selective chromogenic media, making it far and away the most common serotype of STEC identified prior to 2015 when culture independent testing was first implemented in diagnostic laboratories in NZ. Since then, surveillance of all STEC serotypes has become increasingly feasible, including O26:H11, the second most common serotype identified from patient isolates year on year since 2015. Similar to O157:H7, O26:H11 has a high incidence of the 2a sub-type of the Shiga toxin synthesising gene, stx, the most common stx sub-type identified in haemolytic uremic syndrome cases with STEC infections, making O26:H11 stx2a a high-risk seropathotype for personal and public health. Both serotypes demonstrate strong seasonal incidence, although O26:H11 incidence has been steadily increasing in frequency in recent years during Summer months typically dominated by O157:H7, resulting in O26:H11 surpassing O157:H7 as the most common causative agent in haemolytic uremic syndrome cases for 2024 and accounting for 60% of cases in 2025.Risk factors and the demographic groups most affected by this shift in seropathotype will be summarised as well as the difficulty in obtaining comparable surveillance data amongst widespread technological changes in typing.
Source: Figshare
Language: English
Subfield: Microbiology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7164879649
